Outlook Therapeutics, Inc. SEC filings OTLK
Outlook Therapeutics, Inc. has 833 filings in SEC EDGAR's recent list, going back to Aug 10, 2015. Its latest annual report, Form ARS, was filed on Jan 26, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 18, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (listing notice). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 10, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEF 14A | Proxy statement | Jun 1, 2026 | Jul 16, 2026 |
| PRE 14A | Preliminary proxy statement | May 22, 2026 | Jul 16, 2026 |
| DEFA14A | Additional proxy material | Jan 26, 2026 | — |
| DEF 14A | Proxy statement | Jan 26, 2026 | Mar 10, 2026 |
| DEF 14A | Proxy statement | Feb 10, 2025 | Mar 11, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 31, 2025 | Jan 31, 2025 |
| DEF 14A | Proxy statement | Jun 26, 2024 | Aug 12, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 14, 2024 | Aug 12, 2024 |
| DEF 14A | Proxy statement | Feb 8, 2024 | Mar 7, 2024 |
| PRE 14A | Preliminary proxy statement | Jan 29, 2024 | Jan 29, 2024 |
| DEF 14A | Proxy statement | Feb 15, 2023 | Mar 29, 2023 |
| PRE 14A | Preliminary proxy statement | Jan 27, 2023 | Mar 29, 2023 |
| DEF 14A | Proxy statement | Jan 27, 2022 | Mar 23, 2022 |
| DEF 14A | Proxy statement | Feb 22, 2021 | Mar 24, 2021 |
| PRE 14A | Preliminary proxy statement | Feb 10, 2021 | Mar 24, 2021 |
| DEF 14A | Proxy statement | Aug 18, 2020 | Sep 17, 2020 |
| DEFA14A | Additional proxy material | Mar 10, 2020 | — |
| DEF 14A | Proxy statement | Feb 14, 2020 | Mar 19, 2020 |
| PRE 14A | Preliminary proxy statement | Feb 3, 2020 | Mar 19, 2020 |
| DEFA14A | Additional proxy material | Jan 31, 2020 | — |
| DEF 14A | Proxy statement | Aug 1, 2019 | Sep 12, 2019 |
| DEF 14A | Proxy statement | Aug 17, 2018 | Sep 21, 2018 |
| PRE 14A | Preliminary proxy statement | Aug 7, 2018 | Sep 21, 2018 |
| DEFA14A | Additional proxy material | Sep 29, 2017 | — |
| DEF 14A | Proxy statement | Sep 29, 2017 | Oct 26, 2017 |
| PRE 14A | Preliminary proxy statement | Sep 14, 2017 | Sep 14, 2017 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OTLK (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Iselin, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1649989
- Former names
- Oncobiologics, Inc. (until Nov 13, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.